A recent article reviewed the 2023-focused update to the European Society of Cardiology (ESC) heart failure guidelines, which differ from the American guidelines presented in 2022. The ESC guidelines have emphasized the definition changes around HFpEF, which in the U.S. now starts at 50% ejection fraction or greater, with 41%-49% being considered a “mid-range” or mRF category. The article also mentions EMPULSE, a trial that supports initiating SGLT2 inhibitors in a hospital setting rather than waiting for outpatient care. In the U.S., where there have been coverage issues for these drugs, the author advises medical practitioners to ensure their health systems make these drugs accessible. The article highly recommends the updated European guidelines for their clarity and progressive stance on heart failure treatment, including the designation of SGLT2 inhibitors as a class 1A indication.
Reference: Piña I. Heart Failure Guidelines Update: What the ESC Got Right. Medscape. Updated September 08, 2023. Accessed September 19, 2023. https://www.medscape.com/viewarticle/995808
